Golestan University of Medical Sciences Repository

CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies

Safdari, Y. and Ahmadzadeh, V. and Farajnia, S. (2016) CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies. Investigational New Drugs, 34 (4). pp. 497-512.

[img]
Preview
PDF - Published Version
Download (409kB) | Preview

Abstract

Expression of CD20 antigen by the most of transformed B cells is believed to be the driving force for targeting this molecule by using anti-CD20 monoclonal antibodies. While it is true that most lymphoma/leukemia patients can be cured, these regimens are limited by the emergence of treatment resistance. Based on these observations, development of anti-CD20 monoclonal antibodies and combination therapies have been recently proposed, in particular with the aim to optimize the cytotoxic activity. Here we outline a range of new experimental agents concerning the CD20 positive B-cell tumors which provide high benefit from conventional therapy. © 2016, Springer Science+Business Media New York.

Item Type: Article
Additional Information: cited By 0
Subjects: مقالات نمایه شده محققین دانشگاه در سایت ,Web of Science ,Scopus
Divisions: معاونت تحقیقات و فناوری
Depositing User: GOUMS
Date Deposited: 07 Sep 2016 06:56
Last Modified: 26 Sep 2016 10:25
URI: http://eprints.goums.ac.ir/id/eprint/4528

Actions (login required)

View Item View Item